Answers are grounded in this paper and cite their sources.
Aims Gastric cancer poses a significant health burden globally being the fourth leading cause of cancer death. [ 1 ] Its epidemiology varies significantly by region and even within the same country. Although prevention strategies have traditionally relied on risk-factor profiling, the latest ESGE/EHMSG/ESP (MAPS III) guideline update recommends incidence-based endoscopic screening where cost-effectiveness is demonstrated and resources are available, a recommendation largely based on evidences from Asian countries. [ 2 ] Starting from a Western high-risk region, the south-east of Lombardia [ 3 ], we aimed to assess whether OLGA/OLGIM-based surveillance together with epidemiologic risk profiling is sufficient to identify individuals at risk of presenting with dysplastic lesions (DL), early gastric cancer (EGC) or advanced intestinal-type adenocarcinoma (AADK). Methods We conducted a single-center retrospective observational study including patients with DL managed endoscopically, EGC managed endoscopically or surgically and patients with surgically treated AADK at our Hospital in the time span of ten years, from 2015 to 2025. Demographics, risk factor-related informations, dysplastic/neoplastic lesions diagnosis and treatment-related data and background mucosal staging (OLGA/OLGIM) data were collected. All specimens underwent also to a second-look examination by an expert pathologist. Results A total of 153 patients (45 DL, 42 EGC and 66 AADK) with a mean age of 75 years were included in the analysis. The sex distribution showed a slight male predominance (56.9%). Overall, 21.6% of patients were Helicobacter pylori positive at the time of the diagnosis and 17.6% reported a family history of gastric cancer. One of the more relevant findings comes from OLGA/OLGIM staging distribution: 46.6% of patients showed mild-to-moderate atrophy (OLGA I–II), 58.8% mild-to-moderate intestinal metaplasia (OLGIM I-II) and approximatey the 13% of the study population had no atrophy and no intestinal metaplasia at all. Furthermore, no statistically significant differences in OLGA/OLGIM distribution were observed between patients presenting with DL/EGC and the ones affected by AADK (Mann–Whitney U test, Z=–0.570, p=0.569). Conclusions Our findings support the MAPS III guidelines, demonstrating that even in Western countries traditional risk factors for gastric neoplasia are insufficient to identify at-risk individuals in high-incidence areas. Therefore, histology- and risk-factor–based surveillance should be complemented with incidence-based endoscopic screening. Publication History Article published online: 05 June 2026 © 2026. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
No takes yet. Share an insight, caveat, or question.
Sannino et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: